These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7608318)

  • 1. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers.
    Imbimbo BP; Licini M; Schettino M; Mosca A; Onelli E; Zecca L; Giustina A
    J Clin Pharmacol; 1995 Mar; 35(3):285-90. PubMed ID: 7608318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.
    Auteri A; Mosca A; Lattuada N; Luzzana M; Zecca L; Radice D; Imbimbo BP
    Eur J Clin Pharmacol; 1993; 45(4):373-6. PubMed ID: 8299673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers.
    Mant T; Troetel WM; Imbimbo BP
    J Clin Pharmacol; 1998 Jul; 38(7):610-7. PubMed ID: 9702845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid potentiometric determination of cholinesterases in plasma and red cells: application to eptastigmine monitoring.
    Cazzola E; Lattuada N; Zecca L; Radice D; Luzzana M; Imbimbo BP; Auteri A; Mosca A
    Chem Biol Interact; 1993 Jun; 87(1-3):265-8. PubMed ID: 8343985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on the absorption of eptastigmine.
    Bjornsson TD; Troetel WM; Imbimbo BP
    Eur J Clin Pharmacol; 1998 May; 54(3):243-7. PubMed ID: 9681667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs.
    Cella SG; Imbimbo BP; Pieretti F; Müller EE
    Life Sci; 1993; 53(5):389-95. PubMed ID: 8336517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
    Braida D; Sala M
    CNS Drug Rev; 2001; 7(4):369-86. PubMed ID: 11830755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
    Sramek JJ; Block GA; Reines SA; Sawin SF; Barchowsky A; Cutler NR
    Life Sci; 1995; 56(5):319-26. PubMed ID: 7837931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administration of heptylphysostigmine in healthy volunteers: a preliminary study.
    Unni LK; Radcliffe J; Latham G; Sunderland T; Martinez R; Potter W; Becker RE
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):373-6. PubMed ID: 7934317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
    Asthana S; Greig NH; Hegedus L; Holloway HH; Raffaele KC; Schapiro MB; Soncrant TT
    Clin Pharmacol Ther; 1995 Sep; 58(3):299-309. PubMed ID: 7554703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats.
    Scremin OU; Scremin AM; Heuser D; Hudgell R; Romero E; Imbimbo BP
    J Cereb Blood Flow Metab; 1993 Jul; 13(4):702-11. PubMed ID: 8314923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
    Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
    Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
    Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
    Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
    Imbimbo BP; Verdelli G; Martelli P; Marchesini D
    Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eptastigmine improves eight-arm radial maze performance in aged rats.
    Braida D; Ottonello F; Sala M
    Pharmacol Res; 2000 Oct; 42(4):299-304. PubMed ID: 10987987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of mice against soman by pretreatment with eptastigmine and physostigmine.
    Tuovinen K; Hänninen O
    Toxicology; 1999 Dec; 139(3):233-41. PubMed ID: 10647923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of cholinesterase inhibition by eptastigmine in man.
    Unni LK; Hutt V; Imbimbo BP; Becker RE
    Eur J Clin Pharmacol; 1991; 41(1):83-4. PubMed ID: 1782985
    [No Abstract]   [Full Text] [Related]  

  • 20. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
    Greig NH; De Micheli E; Holloway HW; Yu QS; Utsuki T; Perry TA; Brossi A; Ingram DK; Deutsch J; Lahiri DK; Soncrant TT
    Acta Neurol Scand Suppl; 2000; 176():74-84. PubMed ID: 11261809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.